• Hervé Brailly sur BFM TV

    February 16, 2014

    Sébastien Couasnon s'est intéressé à Innate Pharma et à son rachat d'anticorps à Novo Nordisk. Interview d'Hervé Brailly dans Intégrale Bourse

    Si la vidéo ne se lance pas directement, rendez-vous sur http://www.bfmtv.com/

  • Edison Investment Research: An innately compelling story

    January 9, 2014

    Innate Pharma's lirilumab is one of the most promising oncology products being developed. The Phase I trials run by its partner Bristol-Myers Squibb in combination with the high-profile antibodies, ipilimumab and nivolumab, are advancing as expected. Preclinical data presented at December's ASH meeting also indicated that lirilumab might be able to enhance the activity of many other oncology antibodies. Innate Pharma has just raised €20.3m, which will help it develop its pipeline. We raise our valuation to €259m.

  • "Science" Celebrates Cancer Immunotherapy

    December 20, 2013

    Editors of the journal Science ranked cancer immunotherapy at the top of their list of scientific achievements this past year:

    "This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark."

    Read full article

  • Innate Pharma dans le journal Le Monde du 4 décembre 2013

    December 4, 2013

    Les fonds américains convoitent les pépites de la biotechnologie française

    Au cours des dix derniers jours de novembre, l'action d'Innate Pharma a progressé de 75 %. Cet engouement, la société de biotechnologie française, située à Marseille et spécialisée dans l'immuno-oncologie – une approche innovante pour traiter les cancers en dopant le système immunitaire –, le doit aux bonnes fées américaines qui se sont penchées sur son berceau.

  • Innate Pharma coverage on EPvantage.com, November 21, 2013

    November 23, 2013

    Innate financing confirms importance of US to European biotechs


    Innate Pharma this week became the latest European drug developer to turn to the US to seek investor support. The French immuno-oncology company raised €20.3m ($27.3m) in a private placement directed exclusively at investors across the Atlantic, sending its Paris-listed shares to a six-year high.